Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells

Biochemical and Biophysical Research Communications

Volumn 393, Issue 4, 2010, Pages 637-642

  Liu, Xiao Yun ^a   Yang, Yue Feng ^a   Wu, Chu Tse ^a   Xiao, Feng Jun ^a   Zhang, Qun Wei ^a   Ma, Xiao Ni ^b   Li, Qing Fang ^a   Yan, Jun ^a   Wang, Hua ^a   Wang, Li Sheng ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b LANZHOU UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Chronic myeloid leukemia; Cytotoxicity; Imatinib; Mcl 1; Sphingosine kinase 1; Spred2

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; PROTEIN SPRED2; REGULATOR PROTEIN; SPHINGOSINE KINASE 1; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE SILENCING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; REPRESSOR PROTEINS;

ADENOVIRIDAE;

EID: 77949484776     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.02.044     Document Type: Article

References (37)

1. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., Witte O.N., and Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233 (1986) 212-214
2. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996) 561-566
3. McGahon A., Bissonnette R., Schmitt M., Cotter K.M., Green D.R., and Cotter T.G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83 (1994) 1179-1187
4. Ren R.B. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5 (2005) 172-183
5. Puil L., Liu J.X., Gish G., Mbamalu G., Bowtel D., Pelicci P.G., Arlinghaus R., and Pawson1 T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13 (1994) 764-773
6. Goga A., McLaughlin J., Afar D.E.H., Saffran D.C., and Witte O.N. Alternative signals to Ras for hematopoietic transformation by the BCR-ABL oncogene. Cell 82 (1995) 981-988
7. Sawyers C.L., McLaughlin J., and Witte O.N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181 (1995) 307-313
8. Cortez D., Stoica G., Pierce J.H., and Pendergast A.M. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 12 (1996) 2589-2594
9. Pitson S.M., Moretti P.A.B., Zebol J.R., Lynn H.E., Xia P., Vadas M.A., and Wattenberg B.W. Activation of sphingosine kinase 1 by ERK. EMBO J. 22 (2003) 5491-5500
10. Aichberger K.J., Mayerhofer M., Krauth M., Skvara H., Florian S., Sonneck K., Akgul C., Derdak S., Pickl W.F., Wacheck V., Selzer E., Monia B.P., Moriggl R., Valent P., and Sillaber C. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105 (2005) 3303-3311
11. Druker B.J., Telpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
12. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., and Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7 (2007) 345-356
13. Wakioka T., Sasaki A., Kato R., Shouda T., Matsumoto A., Miyoshi K., Tsuneoka M., Komiya S., Baron R., and Yoshimura A. Spred is a Sprouty-related suppressor of Ras signalling. Nature 412 (2001) 647-651
14. Kato R., Nonami A., Taketomi T., Wakioka T., Kuroiwa A., Matsuda Y., and Yoshimura A. Molecular cloning of mammalian Spred-3 which suppresses tyrosine kinase-mediated Erk activation. Biochem. Biophys. Res. Commun. 302 (2003) 767-772
15. Bundschu K., Walter U., and Schuh K. Getting a first clue about SPRED functions. BioEssays 29 (2007) 897-907
16. Miyoshi K., Wakioka T., Nishinakamura H., Kamio M., Yang L., Inoue M., Hasegawa M., Yonemitsu Y., Komiya S., and Yoshimura A. The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization. Oncogene 23 (2004) 5567-5576
17. Nonami A., Kato R., Taniguchi K., Yoshiga D., Taketomi T., Fukuyama S., Harada M., Sasaki A., and Yoshimura A. Spred-1 negatively regulates interleukin-3-mediated ERK/Mitogen-activated Protein (MAP) Kinase activation in hematopoietic cells. J. Biol. Chem. 279 (2004) 52543-52551
18. King J.A.J., Straffon A.F.L., D'abaco G.M., Poon C.L.C., Stacey T.T.I., Smith C.M., Buchert M., Corcoran N.M., Hall N.E., Callus B.A., Sarcevic B., Martin D., Lock P., and Hovens C.M. Distinct requirements for the Sprouty domain for functional activity of Spred proteins. Biochem. J. 388 (2005) 445-454
19. Inoue H., Kato R., Fukuyama S., Nonami A., Taniguchi K., Matsumoto K., Nakano T., Tsuda M., Matsumura M., Kubo M., Ishikawa F., Moon B., Takatsu K., Nakanishi Y., and Yoshimura A. Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness. J. Exp. Med. 201 (2005) 73-82
20. Yoshida T., Hisamoto T., Akiba J., Koga H., Nakamura K., Tokunaga Y., Hanada S., Kumemura H., Maeyama M., Harada M., Ogata H., Yano H., Kojiro M., Ueno T., Yoshimura A., and Sata M. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25 (2006) 6056-6066
21. Nobuhisa I., Kato R., Inoue H., Takizawa M., Okita K., Yoshimura A., and Taga T. Spred-2 suppresses aorta-gonad-mesonephros hematopoiesis by inhibiting MAP Kinase activation. J. Exp. Med. 199 (2004) 737-742
22. Momeny M., Mohammad R.K., Ghaffari S.H., Yousefi M., Yekaninejad M.S., Esmaeili R., Jahanshiri Z., and Nooridaloii M.R. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase. Eur. J. Pharmacol. 591 (2008) 13-20
23. Chatterjee D., Bai Y., Wang Z., Beach S., Mott S., Roy R., Braastad C., Sun Y.P., Mukhopadhyay A., Aggarwal B.B., Darnowski J., Pantazis P., Wyche J., Fu Z., Kitagwa Y., Keller E.T., Sedivy J.M., and Yeung K.C. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J. Biol. Chem. 279 (2004) 17515-17523
24. Baritaki S., Katsman A., Chatterjee D., Yeung K.C., Spandidos D.A., and Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J. Immunol. 179 (2007) 5441-5453
25. Li Q.F., Huang W.R., Duan H.F., Wang H., Wu C.T., and Wang L.S. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene 26 (2007) 7904-7908
26. Bonhoure E., Lauret A., Barnes D.J., Martin C., Malavaud B., Kohama T., Melo J.V., and Cuvillier O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 22 (2008) 971-979
27. Lu Z.Z., Ni F., Hu Z.B., Wang L., Wang H., Zhang Q.W., Huang W.R., Wu C.T., and Wang L.S. Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and 11p. Exp. Hematol. 34 (2006) 1170-1181
28. Li Q.F., Wu C.T., Duan H.F., Sun H.Y., Wang H., Lu Z.Z., Zhang Q.W., Liu H.J., and Wang L.S. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis. Br. J. Haematol. 138 (2007) 632-639
29. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
30. Sridhar S.S., Hedley D., and Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 4 (2005) 677-685
31. Roberts P.J., and Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007) 3291-3310
32. Friday B.B., and Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 14 (2008) 342-346
33. Kato-Stankiewicz J., Hakimi I., Zhi G., Zhang J., Serebriiskii I., Guo L., Edamatsu H., Koide H., Menon S., Eckl R., Sakamuri S., Lu Y., Chen Q.Z., Agarwal S., Baumbach W.R., Golemis E.A., Tamanoi F., and Khazak V. Inhibitors of Ras-Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl. Acad. Sci. USA. 99 (2002) 14398-14403
34. Steelman L.S., Pohnert S.C., Shelton J.G., Franklin R.A., Bertrand F.E., and McCubrey J.A. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18 (2004) 189-218
35. Yu C.R., Krystal G., Varticovksi L., McKinstry R., Rahmani M., Dent P., and Grant S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 62 (2002) 188-199
36. + human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 109 (2007) 4006-4015
37. Copland M., Pellicano F., Richmond L., Allan E.K., Hamilton A., Lee F.Y., Weinmann R., and Holyoake T.L. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111 (2008) 2843-2853